Explore the FDA's initiatives regarding the accessibility of unapproved peptides and associated safety risks.
Analysis of FDA's regulatory changes regarding unapproved peptides
Examination of current evidence on safety and efficacy of these peptides
FDA's plans may lead to greater market availability of unapproved peptides
Concerns arise about inadequate evidence for safety and effectiveness of such products
Abstract
This Medical News article discusses the US Food and Drug Administration’s plans to increase the availability of unapproved peptides for which there is little evidence of safety and efficacy.